Method to reduce inflammatory response in transplanted tissue

Details Method to reduce inflammatory response in transplanted tissue Method to reduce inflammatory response in transplanted tissue

2004-12-02

2008-09-23

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S047000

Reexamination Certificate

active

07427606

ABSTRACT:
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2Aadenosine receptor agonist. If no anti-pathogenic agent is known the A2Aagonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

REFERENCES:
patent: 3892777 (1975-07-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmeichen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4242345 (1980-12-01), Brenner et al.
patent: 4665074 (1987-05-01), Amschler
patent: 4824660 (1989-04-01), Angello et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5593976 (1997-01-01), Mongelli et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5731296 (1998-03-01), Sollevi
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
patent: 5998386 (1999-12-01), Feldman
patent: 6004945 (1999-12-01), Fukunaga
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6020321 (2000-02-01), Cronstein et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117878 (2000-09-01), Linden
patent: 6232297 (2001-05-01), Linden et al.
patent: 6303619 (2001-10-01), Linden
patent: 6322771 (2001-11-01), Linden et al.
patent: 6332771 (2001-12-01), Adams et al.
patent: 6339072 (2002-01-01), Martin et al.
patent: 6350735 (2002-02-01), Monaghan
patent: 6387889 (2002-05-01), Endo et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6624158 (2003-09-01), Mantell et al.
patent: 6670334 (2003-12-01), Linden et al.
patent: 6936596 (2005-08-01), Konno et al.
patent: 7214665 (2007-05-01), Linden et al.
patent: 7226913 (2007-06-01), Linden et al.
patent: 2002/0032168 (2002-03-01), Mantell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0162742 (2003-08-01), Linden et al.
patent: 2005/0282831 (2005-12-01), Beauglehole et al.
patent: 0700908 (1996-03-01), None
patent: 1150991 (2004-04-01), None
patent: 174074 (1979-10-01), None
patent: WO95/11681 (1995-05-01), None
patent: WO96/02553 (1996-02-01), None
patent: WO-9604280 (1996-02-01), None
patent: WO-98/47509 (1998-10-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO99/34804 (1999-07-01), None
patent: WO-99/38877 (1999-08-01), None
patent: WO-99/41267 (1999-08-01), None
patent: WO-99/62518 (1999-12-01), None
patent: WO-99/63938 (1999-12-01), None
patent: WO-99/67263 (1999-12-01), None
patent: WO-99/67264 (1999-12-01), None
patent: WO-99/67265 (1999-12-01), None
patent: WO-99/67266 (1999-12-01), None
patent: WO-00/23457 (2000-04-01), None
patent: WO-00/44763 (2000-08-01), None
patent: WO00/78774 (2000-12-01), None
patent: WO02/09701 (2002-02-01), None
patent: WO02/096462 (2002-12-01), None
patent: WO-03/014137 (2003-02-01), None
Okusa et al., “Selective A2A Adenosine Receptor Activation Reduces Ischemia-Reperfusion Injury in Rat Kidney,” American J. Physiology: Heart and Circulatory Physiology, 277(3, Pt. 2), F404-F412 (Sep. 1999).
Peirce et al., “Selective A2A Adenosine Receptor Activation Reduces Skin Pressure Ulcer Formation and Inflammation,” American J. Physiology: Heart and Circulatory Physiology, 281(1, Pt. 2), H67-H72 (Jul. 2001).
Sullivan et al., “Cyclic AMP-Dependent Inhibition of Human Neutrophil Oxidation Activity by Substituted 2-Propynylcyclohexyl Adenosine A2A Receptor Agonists,” British J. Pharmacology, 132(5), 1017-1026 (2001).
Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, 17th Edition, Merck & Co., Rahway, NJ, Jan. 1999, only pp. 924-925 supplied.
Venes et al. (eds.), Taber's Cyclopedic Medical Dictionary, 19th Edition, F. A. Davis, Philadelphia, PA, 2001, only pp. 960-961 supplied.
Ishiwata et al., “Further Characterization of a CNS Adenosine A2A Receptor Ligand [11C] KF18446 with in vitro Autoradiography and in vivo Tissue Uptake,” Annals of Nuclear Medicine, 14(2), 81-89 (2000).
Sullivan et al., “A2A Adenosine Receptor Activation Improves Survival in Mouse Models of Endotoxemia and Sepsis,” Journal of Infectioous Diseases, 189, 1897-1904 (May 15, 2004).
Moore et al., “A2A Adenosine Receptor Agonists Modify Inflammatory Responses in anE. coliPeritonitis Murine Septic Shock Model,” Abstract(###) from the 43rd Annual Meeting of the Infectious Disease Society of America, Oct. 6-9, 2005, San Francisco, California.
Hogan et al., “Inhibiting the Inflammatory Response in Joint Sepsis,” Arthroscopy, 17(3), 311-315 (Mar. 2001).
Ross et al., “Selective Adenosine A2A Activation Reduces Lung Reperfusion Injury Following Transplantation,” Journal of Heart and Lung Transplantation, 18(1), 994-1002 (Oct. 1999).
Abiru, T., et al., “Nucleosides and nucleotides. 107.2-(cycloalkylalkynyl)adenosines: adenosine A2receptor agonists with potent antihypertensive effects”,Journal of Medicinal Chemistry,35(12), (Jun. 12, 1992), 2253-2260.
Ali, H., et al., “Methylxanthines Block Antigen-induced Responses in RBL-2H3 Cells Independently of Adenosine Receptors or Cyclic AMP: Evidence for Inhibition of Antigen Binding to IgE”,Journal of Pharmacology and Experimental Therapeutics,258, (1991), 954-962.
Andersson, P., et al., “Anti-anaphylactic and anti-inflammatory effects of xanthines in the lung”,Curr. Clin. Pract. Ser.,(1985), 187-192.
Baraldi, Pier G., et al., “Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1and A3Adenosine receptor agonists”,Journal of Medicinal Chemistry,41(17), (Aug. 13, 1998), 3174-3185.
Berkich, D. A., et al., “Evidence of Regulated Coupling of A1Adenosine Receptors by Phosphorylation in Zucker Rats.”,American Journal of Physiology,268 (4), (Apr. 1995), E693-E704.
Bhattacharya, S., et al., “Effects of Long-term Treatment With the Allosteric Enhancer, PD81,723, on Chinese Hamster Ovary Cells Expressing Recombitant Human A1Adenosine Receptors”,Molecular Pharmacology,50(1), (Jul. 1996), 104-111.
Bhattacharya, S., et al., “The Allosteric Enhancer, PD 81,723, Stabilizes Human A1Adenosine Receptor Coupling to G Proteins”,Biochimica et Biophysica Acta,1265 (1), (Feb. 1995),15-21.
Bridges, A.J., et al., “N6-[2-(3,5-Dimethoxyphenyl)-2-(2-Methylphenyl)-Ethyl]Adenosine and Its Uronamide Derivatives. Novel Adenosine Agonists With Both High Affinity and High Selectivity for the Adenosine A2Receptor”,Journal of Medicinal Chemistry,31(7), (Jul. 1988), 1282-1285.
Bruns, R. F., “Adenosine Receptors—Roles and Pharmacology”,Biological Actions of Extracellular ATP, 603, Annals of The New York Academy of Sciences,(1990), 211-22

Affiliated with

Also associated with

Rating

Method to reduce inflammatory response in transplanted tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method to reduce inflammatory response in transplanted tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to reduce inflammatory response in transplanted tissue will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3979699